Form 4: Outlook Therapeutics Director Awarded Stock Options

Director Julian S. Gangolli received stock options for Outlook Therapeutics, Inc. under the company's equity incentive plan.

Summary

• Julian S. Gangolli, a director of Outlook Therapeutics, Inc., was granted stock options on October 1, 2024.
• The options were granted under the Issuer's Non-Employee Director Compensation Policy and the Issuer's 2024 Equity Incentive Plan.
• Gangolli received 56,636 options at an exercise price of $5.22, vesting fully on October 1, 2025, subject to continuous service.
• He also received 71,169 options at an exercise price of $5.22, vesting fully on October 1, 2025, subject to continuous service.
• The options are subject to acceleration upon a Change in Control, provided continuous service is maintained until then.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice, indicating stability and alignment of interests. It's a neutral positive.

Positives

• The stock option grants incentivize the director to remain with the company and contribute to its success.
• The vesting schedule encourages long-term commitment from the director.
• Acceleration upon a Change in Control aligns the director's interests with those of shareholders in such an event.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting and expiration dates of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical.
• The exercise price being equal to the market price on the grant date is also standard practice.

Stakeholder Impact

• The stock option grants could potentially dilute existing shareholders if the options are exercised.
• The grants incentivize the director, which could benefit shareholders through improved company performance.

Key Dates